Heart failure & cardiomyopathiesCohort study
Tirzepatide and the prevention of heart failure in obesity: a multi-center cohort study using the TriNetX database
- Retrospective cohort study
- propensity-score matched
- multicentre
Authors' conclusion
Tirzepatide may reduce the risk of developing HF and improve cardiovascular outcomes in obese individuals.
Study context
- Population
- Adults with obesity (BMI >30 kg/m²), TriNetX global database, January 2022–June 2025matched cohort
- Participants
- 381,026 adults
- Exposure
- Tirzepatide vs no tirzepatide
- Tirzepatiden = 190,513
- Controlsn = 190,513reference
- Outcome
- Incident heart failure (HF)
- Follow-up
- Within one year
Main finding
New-onset HF · 1 year
Hazard ratio
0.53
95% CI 0.50–0.56
P < 0.001
Tirzepatide vs Controls
HR 0.53 (95% CI 0.50–0.56); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR | P value |
|---|---|---|
| All-cause mortality, hospitalization, MACE · 1 year — Tirzepatide vs Controls · all-cause mortality | 0.31 | P < 0.001 |
| All-cause mortality, hospitalization, MACE · 1 year — Tirzepatide vs Controls · hospitalization | 0.46 | P < 0.001 |
| All-cause mortality, hospitalization, MACE · 1 year — Tirzepatide vs Controls · MACE | 0.55 | P < 0.001 |
Subgroups (age, sex, comorbidities, medications)
- Consistent results across subgroups
Original publication
Tirzepatide and the prevention of heart failure in obesity: a multi-center cohort study using the TriNetX database. Eur J Prev Cardiol. Published 22 October 2025. doi:10.1093/eurjpc/zwaf663
Summarised from the published abstract; every number is checked against it